Citation Impact
Citing Papers
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
2014 Standout
DNA Copy Numbers Profiles in Affinity-Purified Ovarian Clear Cell Carcinoma
2010
The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins
2019 StandoutNobel
Epigenetic Resensitization to Platinum in Ovarian Cancer
2012
PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer
2013
An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins
2020 StandoutNobel
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
2010 StandoutScience
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
2022 Standout
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
2020 Standout
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2014 Standout
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
2016
Ovarian cancer
2014 Standout
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
2014
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Cancer stem cells revisited
2017 Standout
Oncolytic viruses: a novel form of immunotherapy
2008
Current Management Strategies for Ovarian Cancer
2007
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
Systemic Therapy for Ovarian Cancer: Current Status and New Treatments
2006
Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses
2015
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
2017 StandoutNobel
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Going viral with cancer immunotherapy
2014
Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results
2011 Standout
Epigenetic treatment of solid tumours: a review of clinical trials
2015
The Role of Hepatocyte Nuclear Factor-1A in the Pathogenesis of Clear Cell Carcinoma of the Ovary
2009
mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model
2022 StandoutNobel
Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses
2016
The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
2010 Standout
Cisplatin: The first metal based anticancer drug
2019 Standout
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
2015 Standout
Type I Interferon in Chronic Virus Infection and Cancer
2017
Endometriosis: pathogenesis and treatment
2013 Standout
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Using sulfuramidimidoyl fluorides that undergo sulfur(vi) fluoride exchange for inverse drug discovery
2020 StandoutNobel
Oncolytic virotherapy
2012
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas
2010 StandoutNobel
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
2016
Management of glioblastoma: State of the art and future directions
2020 Standout
Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience
2005
Current Management Strategies for Ovarian Cancer
2007
Ovarian Cancer
2008
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
2018 Standout
Photoactivated platinum-based anticancer drugs
2018
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth
2011 Standout
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
2010 Standout
Combination therapy strategies for improving PD‐1 blockade efficacy: a new era in cancer immunotherapy
2017 StandoutNobel
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
2014 StandoutNobel
Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer
2007
Characterization of DNA Methylation in Circulating Tumor Cells
2015
E3 ubiquitin ligase Mindbomb 1 facilitates nuclear delivery of adenovirus genomes
2020 StandoutNobel
Phase III Trial of Observation Versus Six Courses of Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer in Complete Response After Six Courses of Paclitaxel/Platinum-Based Chemotherapy: Final Results of the After-6 Protocol 1
2009
Works of Geoff Hall being referenced
Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies
2012
Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridisation
2003
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
2016
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer
2014
The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma
2010
Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice
2010
Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study
2004
Treg Depletion–enhanced IL-2 Treatment Facilitates Therapy of Established Tumors Using Systemically Delivered Oncolytic Virus
2008
Principles of cancer treatment by chemotherapy
2009
OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC).
2016